Grifols Gains FDA Updated Approval for Procleix Babesia Assay on Panther System

Blood bank QA directors and biologics facility compliance leads should note that Grifols Diagnostics Solutions Inc. received an updated FDA approval letter on June 10, 2026, covering the Procleix Babesia Assay alongside the Procleix WNV Assay and Procleix Ultrio Elite Assay on the Procleix Panther System. The update extends a regulatory history dating to the assay's original approval in January 2019 and reflects continued agency engagement with the platform's donor screening scope.

The Procleix Babesia Assay is a qualitative nucleic acid amplification test (NAT) designed to detect RNA from four Babesia species: B. microti, B. duncani, B. divergens, and B. venatorum. Its cleared indications cover screening of individual donors of whole blood and blood components, living organ and tissue donors, and cadaveric (non-heart-beating) donors specifically for B. microti. Facilities running the assay must observe a critical pooling constraint: lysed individual donor whole blood samples may be tested individually or in pools of equal aliquots not exceeding 16; cadaveric donor specimens must be tested individually and cannot be pooled.

For quality systems leads, the distinction between pooled and individual testing protocols carries direct procedural weight. SOPs governing donor screening workflows on the Panther System will need to reflect the cadaveric specimen restriction explicitly, and any deviation from the pool-size ceiling of 16 would represent a departure from labeled use. The assay carries an explicit exclusion for cord blood specimens and is not indicated as a diagnostic aid for Babesia infection, a boundary that should be reflected in both operator training documentation and any associated 21 CFR Part 606 records.

The June 2026 letter is the sixth approval action on this assay since 2019, a cadence that signals ongoing label refinements rather than a static cleared indication. Facilities that have previously validated the Procleix Babesia Assay against earlier approval letters should assess whether the June 10, 2026 update introduces any changes to the package insert that affect their current validation status or require requalification under their process validation frameworks.

Blood establishments and tissue facilities subject to FDA biologics regulations under 21 CFR Parts 606 and 1271 should review the updated package insert against current SOPs before the next scheduled internal audit cycle.

Source: FDA Vaccines, Blood and Biologics via FDA.gov RSS Feed, June 15, 2026.